INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Dermatophytes are a major cause of fungal infections worldwide, and they are quite common in developing countries. Recent studies show that these infections have been increasing notably in India, particularly in the last few years. The rise in recurrent or chronic cases has made it clear that we need novel drug therapies for dermatophytosis treatment. Also, there is a worrying increase in resistance to the usual oral and topical antifungal medicines. Novel formulations or newer derivatives of existing drug classes and few newer drug classes are being developed by researchers for the treatment of chronic or extensive dermatophytosis. Newer topical drugs include efinaconazole, tavaborole, ciclopirox HPCH lacquer, econazole and luliconazole. Additional forms of local therapies including photodynamic therapy and laser irradiation are also recommended for dermatophytosis treatment.
"Novel Drug Therapies in the Treatment of Dermatophytosis", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 3, page no.e410-e414, March-2024, Available :http://www.ijnrd.org/papers/IJNRD2403451.pdf
Downloads:
00031
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn